Hikma Expects To Gain FDA Approval For Advair Diskus In Early 2021
22 Settembre 2020 - 9:48AM
Alliance News
Hikma
Pharmaceuticals PLC said Tuesday it has been given a "minor"
complete response letter by the US Food & Drug Adm ...
Subscribe now to see this Premium News
article from
Alliance News Professional covers every UK
stock in your portfolio. It goes beyond regulatory news and free
web services to give your investment decisions an edge over the
crowd.
- In The
Know - Management and analyst comments that go beyond company
announcements.
- Flash headlines on all 2,400 London-listed companies before the
news hits the open web.
- Broker Ratings - The
earliest tip-offs, many before the market opens.
- Economic data and central bank flashes from UK, US and
eurozone.
- Taking
AIM - Up to the minute market commentary on AIM stocks.
- Over 500 news items per trading day for just £39.60 per month,
and cancel at any time.
Call us on +44 (0) 203 8794 460 to get
started.
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024